-
Product Insights
Retinal Degeneration – Drugs In Development, 2023
Global Markets Direct’s, ‘Retinal Degeneration - Drugs In Development, 2023’, provides an overview of the Retinal Degeneration pipeline landscape. The report provides comprehensive information on the therapeutics under development for Retinal Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Epidermolysis Bullosa – Drugs In Development, 2023
Global Markets Direct’s, ‘Epidermolysis Bullosa - Drugs In Development, 2023’, provides an overview of the Epidermolysis Bullosa pipeline landscape. The report provides comprehensive information on the therapeutics under development for Epidermolysis Bullosa, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Optic Neuropathy – Drugs In Development, 2023
Global Markets Direct’s, ‘Optic Neuropathy - Drugs In Development, 2023’, provides an overview of the Optic Neuropathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Optic Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Juvenile Macular Degeneration (Stargardt Disease) – Drugs In Development, 2023
Global Markets Direct’s, ‘Juvenile Macular Degeneration (Stargardt Disease) - Drugs In Development, 2023’, provides an overview of the Juvenile Macular Degeneration (Stargardt Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Juvenile Macular Degeneration (Stargardt Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Hydrogels Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Hydrogels Pipeline Market Report Overview Hydrogels include dressings that consist of 96% water with a matrix of insoluble polymers embedded in it. The former helps to maintain a moist wound environment while the latter facilitates absorption of wound exudates. These dressings are available in the form of tubes and sheets and both of them are tracked under this segment. Hydrogels are segmented into antimicrobial and non-antimicrobial hydrogel dressings. The Hydrogels pipeline market research report provides comprehensive information about the Hydrogels...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ART-0380 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ART-0380 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ART-0380 in Solid Tumor Drug Details: ART-0380 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Prademagene Zamikeracel in Epidermolysis Bullosa
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Prademagene Zamikeracel in Epidermolysis Bullosa report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Prademagene Zamikeracel in Epidermolysis Bullosa Drug Details: Prademagene zamikeracel (EB-101) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RP-2 in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RP-2 in Metastatic Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.RP-2 in Metastatic Colorectal Cancer Drug Details:RP-2 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – PanBlok in Pandemic Influenza
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PanBlok in Pandemic Influenza report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.PanBlok in Pandemic InfluenzaDrug Details:PanBlok (UMN-0501) is under development for the treatment of pandemic...
-
Company Profile
Abeona Therapeutics Inc – Company Profile
Abeona Therapeutics Inc (Abeona), formerly PlasmaTech Biopharmaceuticals Inc, is a biopharmaceutical company that develops and delivers gene therapy and plasma-based products for severe life-threatening rare diseases. The company’s lead programs include EB-101, ABO-101 and ABO-102 adeno-associated virus. Abeona develops EB-101 for recessive dystrophic epidermolysis bullosa (RDEB), EB-201 for epidermolysis bullosa (EB), ABO-202 (AAV-CLN1) gene therapy for the treatment of infantile Batten disease (INCL), ABO-201 (AAV-CLN3) gene therapy for Juvenile Batten disease (JNCL) and more. The company has partnerships for the...
Add to Basket